The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

被引：0
|
作者：
Hongping Chen
Da Teng
Bowen Xu
Chunxiao Wang
Hua Wang
Wenjuan Jia
Lei Gong
Haibin Dong
Lin Zhong
Jun Yang
机构：
[1] Qingdao University,School of Medicine
[2] Yuhuangding Hospital,Department of Cardiology
[3] The Fourth School of Clinical Medicine of Qingdao University,undefined
[4] Binzhou Medical University,undefined
来源：
Journal of Cardiovascular Translational Research | 2023年 / 16卷
关键词：
SGLT2 inhibitor; Macrophage; Autophagy; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：999 / 1009
页数：10
相关论文
共 50 条
  • [41] Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis
    Martus, Giedre
    Bergling, Karin
    Oberg, Carl M.
    PERITONEAL DIALYSIS INTERNATIONAL, 2023, 43 (02): : 145 - 150
  • [42] The SGLT2 Inhibitor Canagliflozin Prevents Increased Lipid Oxidation in the Heart following High-Fat Feeding
    Flores, Itzel
    Shannon, Chris
    Fourcaudot, Marcel
    Bakewell, Terry
    Norton, Luke
    DIABETES, 2019, 68
  • [43] Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
    Furuhashi, Masato
    Matsumoto, Megumi
    Hiramitsu, Shinya
    Omori, Akina
    Tanaka, Marenao
    Moniwa, Norihito
    Yoshida, Hideaki
    Ishii, Junnichi
    Miura, Tetsuji
    PLOS ONE, 2016, 11 (04):
  • [44] Application of an Updated Oral Glucose Minimal Model in Subjects with Type 2 Diabetes Treated with the SGLT2 Inhibitor Canagliflozin
    Piccinini, Francesca
    Bergman, Richard N.
    Polidori, David
    DIABETES, 2017, 66 : A337 - A338
  • [45] The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
    Chowdhury, Biswajit
    Luu, Albert Z.
    Luu, Vincent Z.
    Kabir, M. Golam
    Pan, Yi
    Teoh, Hwee
    Quan, Adrian
    Sabongui, Sandra
    Al-Omran, Mohammed
    Bhatt, Deepak L.
    Mazer, C. David
    Connelly, Kim A.
    Verma, Subodh
    Hess, David A.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 524 (01) : 50 - 56
  • [46] The SGLT2 inhibitor, empagliflozin reduces early progressive proteinuria in obese SS rats
    Ekperikpe, Ubong
    Daniels, Jacori
    Mandal, Sautan
    Cooper, Jonita
    Johnson, Tyler
    Safir, Sarah
    Cornelius, Denise
    Williams, Jan
    PHYSIOLOGY, 2023, 38
  • [47] SGLT2 Inhibitor Reduces eGFR Variability Leading to Improve eGFR Slope in CKD
    Nakano, Yukihito
    Sakaguchi, Mika
    Nakatani, Yoshihisa
    Arima, Shuji
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 575 - 575
  • [48] Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-induced Hepatic Steatosis in Albino Rats
    Ahmed, Eman, I
    Shaaban, Amany M.
    Latif, Abdel Karim M. Abdel
    CURRENT DRUG THERAPY, 2020, 15 (03) : 274 - 282
  • [49] The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
    Day, Emily A.
    Ford, Rebecca J.
    Lu, Jessie H.
    Lu, Rachel
    Lundenberg, Lucie
    Desjardins, Eric M.
    Green, Alex E.
    Lally, James S., V
    Schertzer, Jonathan D.
    Steinberg, Gregory R.
    BIOCHEMICAL JOURNAL, 2020, 477 (12) : 2347 - 2361
  • [50] SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
    Zhao, Xin-yu
    Li, Shuang-shuang
    He, Ying-xin
    Yan, Li-jie
    Lv, Fu
    Liang, Qi-meng
    Gan, Yu-hui
    Han, Li-pei
    Xu, Hong-de
    Li, Yong-chun
    Qi, Yuan-yuan
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (10) : 1328 - 1340
12345